Watson D L, Carpenter C L, Marks S S, Greenberg D A
Department of Neurology, University of California, San Francisco.
Ann Neurol. 1988 Mar;23(3):303-5. doi: 10.1002/ana.410230316.
The density of calcium channel antagonist receptors labeled by (+)-[3H]PN 200-110 was reduced by 75% in striata from patients with Huntington's disease, but unchanged in patients with Parkinson's disease, compared with control subjects. These receptors are therefore likely to be localized to neurons with cell bodies in striatum, rather than nigrostriatal nerve terminals or glia, and their loss may contribute to the pathophysiology of basal ganglia disorders.
与对照受试者相比，亨廷顿舞蹈症患者纹状体中由（+）-[3H]PN 200-110标记的钙通道拮抗剂受体密度降低了75%，而帕金森病患者纹状体中的该受体密度无变化。因此，这些受体可能定位于细胞体在纹状体中的神经元，而非黑质纹状体神经末梢或神经胶质细胞，其丧失可能促成基底神经节疾病的病理生理学过程。
